Edward Nash
Stock Analyst at Canaccord Genuity
(4.20)
# 403
Out of 4,847 analysts
81
Total ratings
46.48%
Success rate
17.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $394 → $420 | $278.80 | +50.65% | 9 | May 2, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $64 | $19.93 | +221.12% | 1 | Apr 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $15.39 | +205.39% | 10 | Apr 10, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $130 → $142 | $69.07 | +105.59% | 7 | Apr 1, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.56 | +1,518.56% | 2 | Feb 26, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $44 → $72 | $84.64 | -14.93% | 9 | Feb 12, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.59 | +151.57% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $51.21 | +42.55% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $37.32 | +138.48% | 1 | Nov 25, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $2.01 | +596.52% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.33 | +503.77% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $3.58 | +458.30% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $2.65 | +201.89% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $4.41 | +285.49% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.28 | -12.28% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.46 | +12,228.77% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $36.62 | +123.92% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $2.53 | +3,062.06% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $15.23 | +215.17% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $6.34 | +10,152.37% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $394 → $420
Current: $278.80
Upside: +50.65%
Celldex Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $64
Current: $19.93
Upside: +221.12%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $15.39
Upside: +205.39%
Corcept Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $130 → $142
Current: $69.07
Upside: +105.59%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.56
Upside: +1,518.56%
Verona Pharma
Feb 12, 2025
Maintains: Buy
Price Target: $44 → $72
Current: $84.64
Upside: -14.93%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.59
Upside: +151.57%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $51.21
Upside: +42.55%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $37.32
Upside: +138.48%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $2.01
Upside: +596.52%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.33
Upside: +503.77%
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $3.58
Upside: +458.30%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $2.65
Upside: +201.89%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $4.41
Upside: +285.49%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.28
Upside: -12.28%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.46
Upside: +12,228.77%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $36.62
Upside: +123.92%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $2.53
Upside: +3,062.06%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $15.23
Upside: +215.17%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $6.34
Upside: +10,152.37%